



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Equine induced Pluripotent Stem Cell culture

**Citation for published version:**

Falk, J & Donadeu, X 2023, Equine induced Pluripotent Stem Cell culture. in M Baratta (ed.), *Methods in Molecular Biology*. vol. 2749, Epithelial Cell Culture, Springer Nature, pp. 175-184.  
<https://doi.org/10.1007/978-1-0716-3609>

**Digital Object Identifier (DOI):**

[10.1007/978-1-0716-3609](https://doi.org/10.1007/978-1-0716-3609)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Methods in Molecular Biology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



## Chapter x

### 1 **Equine induced Pluripotent Stem Cell culture**

2 Julia Falk<sup>1\*</sup> and F. Xavier Donadeu<sup>1</sup>

3 <sup>1</sup> Division of Translational Bioscience, The Roslin Institute, University of Edinburgh, Easter  
4 Bush, Midlothian, United Kingdom

5

6 \*Corresponding author: Julia Falk, The Roslin Institute and R(D)SVS, University of  
7 Edinburgh, Easter Bush, Midlothian, United Kingdom. [J.Falk-1@sms.ed.ac.uk](mailto:J.Falk-1@sms.ed.ac.uk)

8

9

10

11

12

13 Running head: culture of equine iPSCs

14

15

16

17

18

19

20 **i. Abstract**

21 Ground-breaking work by Takahashi and Yamanaka in 2006 demonstrated that non-  
22 embryonic cells can be reprogrammed into pluripotent stem cells (PSCs) by forcing the  
23 expression of a defined set of transcription factors in culture, thus overcoming ethical  
24 concerns linked to embryonic stem cells. Induced PSCs have since revolutionized  
25 biomedical research, holding tremendous potential also in other areas such as livestock  
26 production and species conservation. iPSCs exhibit broad accessibility, having been  
27 derived from a multitude of cell types and species. Apart from humans, iPSCs hold  
28 particular medical promise in the horse. The potential of iPSCs has been shown in a  
29 variety of biomedical contexts in the horse. However, progress in generating  
30 therapeutically useful equine iPSCs has lagged behind that reported in humans, with  
31 the generation of footprint-free iPSCs using non-integrative reprogramming approaches  
32 having proved particularly challenging. A greater understanding of the underlying  
33 molecular pathways and essential factors required for the generation, and maintenance  
34 of equine iPSCs and their differentiation into relevant lineages will be critical for  
35 realising their significant potential in veterinary regenerative medicine. This article  
36 outlines up-to-date protocols for the successful culture of equine iPSC, including colony  
37 selection, expansion, and adaptation to feeder-free conditions.

38

39 **Key Words:**

40 Equine, iPSCs, cell reprogramming, feeder-free culture

41

42

## 43 1. Introduction

44 Induced pluripotent stem cells (iPSCs) have significantly transformed biomedicine,  
45 owing to their immense potential in disease modelling, drug screening and cell-based  
46 therapies, in addition to highly exciting non-medical applications such as species  
47 conservation.<sup>1,2</sup> Back in 2006, ground breaking work by Takahashi and Yamanaka  
48 demonstrated that by introducing a combination of four transcription factors (OCT4,  
49 SOX2, c-MYC, and Klf4, referred to as OSKM), non-embryonic cells could be  
50 reprogrammed to a developmental state akin to embryonic stem cells (ESCs). As such,  
51 iPSC are devoid of the ethical concerns associated with the use of embryos.<sup>3</sup>  
52 Remarkably, iPSCs have been derived from most cell types, including for example  
53 urine-derived cells<sup>4</sup>, and from a multitude of species, making them easily accessible for  
54 research purposes.<sup>1</sup> Moreover, through their large developmental plasticity and ability  
55 to differentiate into a variety of cell lineages, iPSCs provide powerful tools for a wide  
56 array of applications in biomedical research and therapy.<sup>1</sup>

57 As well as human medicine, iPSC technology holds significant promise in veterinary  
58 species, specifically in horses, in which stem cell therapies are already well established  
59 and could considerably benefit, in terms of improved efficacy, from the introduction of  
60 iPSCs.<sup>5</sup>

61 Non-integrative or excisable reprogramming methods including Sendai virus, episomal  
62 vectors, RNA-based technologies or piggyBac expression systems provide a feasible  
63 route to the therapeutic use of iPSCs, and are now routinely employed to reprogram  
64 human cells<sup>6-8</sup>. However, the use of these approaches with horse cells has met with  
65 little success<sup>9,10</sup>, leading to the predominant use of integrating viral systems to generate  
66 equine iPSC lines.<sup>5</sup>

67 Moreover, advancements in iPSC technology have led to the elimination of xeno- and  
68 animal-dependent cultures in favour of feeder-free conditions. This involves  
69 substituting feeders with a suitable coating matrix and using serum replacement or  
70 small-molecule cocktails in the place of fetal bovine serum (FBS).<sup>11</sup> Thus, numerous  
71 clinical-grade products are available to support growth of iPSCs from humans and  
72 rodents, but the culture of iPSCs from domestic species still relies heavily on the use of  
73 feeders<sup>5,12</sup>. Yet, transitioning to feeder-free iPSCs will be imperative for any future  
74 therapeutic applications for horses.

75 Considering how slow the field of equine iPSCs has advanced compared to human and  
76 mouse, gaining a better understanding of the molecular pathways and critical factors  
77 involved in the generation and maintenance of equine iPSCs will be crucial.

78 The protocols in this article have been successfully used over the years in our laboratory  
79 to grow equine iPSCs of different origins and generated using different approaches.  
80 Hopefully their use will aid future advancements in realising the significant potential  
81 of these cells in veterinary regenerative medicine.

82

## 83 **2. Materials**

### 84 **2.1 Cell culture equipment**

- 85 1. 70 % Ethanol for surface sterilisation
- 86 2. Class 2 biological safety hoods
- 87 3. Laminar flow hood
- 88 4. Water bath set at 37°C
- 89 5. Inverted Microscope
- 90 6. Neubauer Hemocytometer (or other cell counting device)

- 91 7. Incubator, suitable for cell culture (set to 37 °C, 21% O<sub>2</sub>, 5% CO<sub>2</sub>, 95% relative  
92 humidity)
- 93 8. Centrifuges (suitable for small tubes, and 15-50mL tubes)
- 94 9. Sterile cell culture plastic pipettes and pipette tips
- 95 10. Sterile centrifuge tubes in various sizes
- 96 11. Different size multi well tissue culture plates and flasks
- 97 12. GammaCell 1000 irradiator
- 98 13. Syringe with 18G x 1 1/2" (1.2 x 40 mm) needle

99

## 100 2.2 Cell culture reagents

- 101 1. Phosphate-buffered saline (PBS)
- 102 2. **Mouse embryonic fibroblast (MEF) media:** DMEM, high glucose (41965039,  
103 Thermo Fisher), 10%FBS, 0.1mM MEM Non-Essential Amino Acids (NEAA), 2mM  
104 L-glutamine and Penicillin/Streptomycin (stable for up to 4 weeks at 4 °C).
- 105 3. **Equine iPSC media:** DMEM, high glucose (41965039, Thermo Fisher) containing  
106 20% FBS or KnockOut™ Serum Replacement (10828028, Thermo Fisher), 1x  
107 GlutaMAX™ (35050061, Thermo Fisher) 0.1mM β-mercaptoethanol, 0.1 mM MEM  
108 non-essential amino acids and 1% penicillin-streptomycin supplemented with 10 ng/ml  
109 human bFGF and 1000 U/mL human LIF (should be prepared before use and stable  
110 for up to 7 days at 4 °C).
- 111 4. **Equine embryonic fibroblast (EEF) media** used to prepare conditioned media (CM):  
112 KnockOut™ DMEM (10829018, Thermo Fisher) containing 20% KnockOut™ Serum  
113 Replacement (10828028, Thermo Fisher), 1x GlutaMAX™ (35050061, Thermo  
114 Fisher) 0.1mM β-mercaptoethanol, 0.1 mM MEM non-essential amino acids and 1%  
115 penicillin-streptomycin (stable for up to 4 weeks at 4 °C).
- 116 5. **Trypsin-EDTA** (0.05%), phenol red (25300054, Thermo Fisher)
- 117 6. **StemPro™ Accutase™ Cell Dissociation Reagent** (A1110501, Thermo Fisher)
- 118 7. **Corning® Matrigel® Matrix** Before use, thaw stock solution at 4°C to avoid gel  
119 formation and dilute as appropriate in cold DMEM. Then coat tissue culture plates and

120 flasks overnight at 4°C or at 37 °C for 1h and use immediately or stored sealed at 4°C  
121 for up to a week.

122 8. **Gelatin:** Before use, dilute 2% gelatin solution (G1393, Sigma-Aldrich) in PBS to  
123 0.1% working solution. Cover tissue culture plastic surfaces with working solution and  
124 incubate for 15 min at 37°C, use immediately or stored sealed at 4°C for up to a week.

125 9. **Freezing media:** 10 % (v/v) DMSO (cell culture grade), 90 % (v/v) FBS

## 126 **2.3 Cell stocks**

127 1. Equine iPSCs

128 2. MEFs

129 3. EEFs

## 130 **3 Methods**

### 131 **3.1 Preparation of MEF feeder cells**

132 This protocol describes the preparation of irradiated MEF feeder cells for culture of equine  
133 iPSCs (see **Note 1**).

- 134 1. Use low passage MEFs grown in suitable culture vessel with MEF media.
- 135 2. When ready for irradiation, detach cells by incubating for 2-8 min with trypsin at 37  
136 °C, then spin at 300 x g for 5min, and re-suspend in fresh pre-warmed media. Count  
137 cells on hemacytometer and re-plate in suitable vessel at  $5.7 \times 10^3$  cells/cm<sup>2</sup> to expand  
138 further or proceed to irradiation as described below.
- 139 3. For irradiation add desired cell number in 50 mL falcon in culture media and expose to  
140 12.5 Gray in Gamma Irradiator.
- 141 4. Plate cells immediately (see step 7) or freeze down in freezing media for later use (see  
142 **Note 2**).
- 143 5. One day before plating iPSC culture, coat wells in a culture vessel of desired size with  
144 0.1% gelatin solution and incubate for 15min at 37 °C. Use immediately or store sealed  
145 at 4 °C for up to 7 days.
- 146 6. Quickly thaw stock of irradiated MEFs by placing in 37 °C water bath and then dilute  
147 in MEF culture media. Centrifuge cells 300 x g for 5 min at RT. Discard supernatant  
148 and resuspend in fresh MEF media.
- 149 7. Seed MEFs in gelatin coated surfaces ( $2 \times 10^6$  cells per 6-well plate; see **Note 3**) and  
150 culture overnight to allow cell attachment before use for iPSC culture.

151

### 152 **3.2 Picking, expansion and culture of equine iPSC colonies on feeder cells**

153 Equine iPSCs can be generated using different reprogramming approaches, and relevant  
154 protocols have been published<sup>9,13,14</sup>. The present is a protocol for establishing and maintaining  
155 iPSC lines in feeder culture once bona fide colonies have been generated using one of the  
156 approaches above, and describes the selection of individual iPSC colonies and their subsequent  
157 expansion in culture.

- 158 1. Individual colonies should be selected for clonal expansion based on assessment by  
159 daily microscope inspection. Colonies selected for picking should show clear growth  
160 and appear compact with well-defined edges. Colonies observed to increase in size  
161 for 2-4 days and devoid of a dark area in the center should be picked (Figure 1).
- 162 2. One day before picking, prepare MEF feeders in 96- or, alternatively, 24-well plates  
163 (see 3.1).
- 164 3. It is easiest to pick the colonies under a microscope or stereomicroscope, which is  
165 integrated into a laminar flow hood. Alternatively, a microscope can be brought into  
166 the hood while leaving the glass shield fully open and taking care to work as much as  
167 possible under aseptic conditions (e.g. avoid external airflow from people walking  
168 past, and work as quick as possible once culture dish is open).
- 169 4. Position the colony directly under the microscope and use a 20uL pipette to carefully  
170 pick the colony by gentle aspiration. Then transfer onto well containing feeders in  
171 equine iPSC media and visualize under microscope to confirm the transfer has been  
172 successful by identifying the colony. If picking proves difficult, try using a syringe to  
173 cut the colony out before aspirating.
- 174 5. Repeat as above for other colonies as required, and place each in a separate well.
- 175 6. Culture picked colonies overnight and then confirm each has attached to feeder layer.  
176 Colonies should start proliferating 2-4 days after picking. If colony shows no sign of  
177 growth after 7 days of picking, they can be discarded. Once it has been proliferating  
178 for 3-5 days, and as long as the center is not turning dark or there are no signs of  
179 differentiation, a colony should be split for expansion into a larger vessel (24 or 12-  
180 well size) with fresh MEF feeders. Splitting can be done by mechanical disruption  
181 (see 3.2.7) or using Accutase (see 3.2.8).



- 182 7. To disrupt a colony mechanically use a microscope set up as described in Step 3.2.3.  
183 Put the colony in focus under the microscope and use a syringe to carefully cut it into  
184 4-8 pieces. Carefully aspirate the pieces with a 20- or 100uL pipette and transfer into  
185 a well with fresh feeders. If multiple colonies in a well are disrupted, then media in  
186 the well should be aspirated in its entirety and spun for 4 min 200 x g, before carefully  
187 resuspending in fresh culture media.
- 188 8. To dissociate colonies with Accutase, carefully aspirate the media and wash with  
189 PBS. Add enough Accutase to cover the surface of the well. Place in incubator for 2-  
190 8 min and observe cells under microscope. When the outside of the colony starts to  
191 lift (cells will seem brighter) and colony becomes less compact, add equine iPSC  
192 media to stop reaction. Use 1mL pipette to carefully scrape and disrupt iPSCs, before  
193 aspirating. Do not pipette cells up and down more than twice, to avoid disruption into  
194 single cells. Spin down cells for 4 min 200 x g, then carefully resuspend in fresh  
195 culture media and plate on new feeders.
- 196 9. After splitting cells into larger vessel as described above, check daily to ensure  
197 colonies keep their compact morphology with clear edges. If cells become confluent,  
198 use Accutase as above to split into larger vessel (6-well plate).
- 199 10. iPSC cells can be maintained from then on in 6-wells plates using equine iPSC media  
200 e(or other suitable media that has been previously optimized). Typically cells need to  
201 be split every 3-5 days at a ratio of 1:4-1:10 depending on the culture (See **Note 4**).

202

### 203 **3.4 Growth of equine iPSCs in feeder free culture**

204 Feeder-free culture greatly facilitates work with iPSCs and it is a requirement for many  
205 downstream applications, whether involving their use as in vitro models or in prospective  
206 therapeutic applications. As reprogramming of equine cells is simpler using feeder layers,  
207 feeder-free cultures usually result from adaptation of iPSC lines generated on feeders<sup>13</sup>.  
208 However, adaptation to feeder free conditions can be challenging. Choosing the right coating  
209 substrate and culture media is crucial, and different combinations may need to be tested in each  
210 particular instance. The following protocol uses matrigel and EEF CM. It was originally used  
211 to adapt iPSCs generated through reprogramming of equine keratinocyte with retroviral  
212 vectors, and has later been successfully used with other equine iPSC lines in our laboratory.<sup>13</sup>

- 213 1. Harvest CM from confluent layers of mitotically inactivated EEFs (see **Note 5**) in T175  
214 flasks at 37 °C and 5% CO<sub>2</sub>. Do this by collecting and replacing EEF media daily from  
215 each flask for a total of 5 days. Stock store collected media at -20C until use. Discard  
216 cells after the 5 days. Before use, supplement the conditioned media with 10 ng/ml  
217 human bFGF and 1000 U/mL human LIF (keep at 4 °C for up to 7 days).
- 218 2. Start transition to feeder-free culture by gradually reducing feeder density during iPSC  
219 passaging. When preparing feeders before iPSC passaging, plate 75% of the usual  
220 feeder number (e.g. if normally using  $2 \times 10^6$  per well of a 6 Well plate, reduce to  $1.5 \times 10^6$   
221 per well). Split iPSC culture as usual using prepared feeders.
- 222 3. Monitor morphology of passaged iPSCs and use same feeder density for at least one  
223 more passage. After transition to reduced feeders some iPSC colonies may undergo  
224 morphology changes indicative of loss of pluripotency (Figure 2). In that case, try to  
225 remove abnormal colonies mechanically and keep the rest of the culture growing. If on  
226 the contrary only a few colonies maintain typical morphology, then try to pick those  
227 and plate them in smaller vessel (see 3.2.1), and discard the rest. Once colonies are  
228 growing well, move on to next step.
- 229 4. In the next step reduce feeder density to 50% of the original following the same  
230 principle as in 3.4.2. In addition, when plating cells on reduced feeder density, replace  
231 half of equine iPSC media with CM collected in Step 3.4.1. Follow same procedures as  
232 in Step 3.4.3.
- 233 5. Once colonies are growing well in 50% feeder density, then prepare a Matrigel coated  
234 culture dish and seed feeders at 25% of the original density. Passage iPSCs onto reduced  
235 feeders and culture in 100% CM.
- 236 6. Follow same procedures as in Step 3.4.3 (See **Note 6**).
- 237 7. Once colonies are growing well on a minimal amount of feeders, then passage onto  
238 Matrigel only and 100% CM.
- 239 8. Follow same procedures as in Step 3.4.3.
- 240 9. Continue to expand cells in feeder free conditions as in 3.4.7 and confirm cells maintain  
241 normal karyotype once adapted.

#### 242 4. Notes

- 243 1. In addition to MEFs, equine embryonic fibroblasts or SNLs can be used successfully as  
244 feeder layers to generate and maintain equine iPSCs. These cells can be inactivated  
245 either by the use of  $\gamma$ -irradiation or mitomycin C treatment.<sup>5,15</sup>
- 246 2. It is useful to freeze irradiated MEFs at a “working concentration” e.g. in vials each  
247 containing the required amount for seeding a 6-well plate( $2 \times 10^6$  MEF per 6-well plate).
- 248 3. Feeder cell density may need to be optimised based on the performance of iPSC  
249 cultures.
- 250 4. Once colonies have been expanded into multiple wells, further optimization of  
251 dissociation method and/or culture media can be performed if needed, by determining  
252 in the first instance growth rate and morphology of colonies under different conditions.  
253 Different media may be suitable for culture of equine iPSC, including chemically  
254 defined media.<sup>5,10</sup>
- 255 5. Our laboratory has always used fibroblasts derived from the same single equine fetus<sup>13</sup>,  
256 therefore the effects of fetal age (and other potential variables) on the suitability of  
257 EEFs for iPSC culture are yet to be determined.
- 258 6. If at this point colonies stop growing or loose typical iPSC morphology, then changing  
259 culture conditions should be attempted. Different coating matrix and culture media  
260 combinations can be tried to establish feeder-free culture. Matrigel can be replaced  
261 with Vitronectin, Laminin-521<sup>16,17</sup> or other commercially available matrices, in  
262 combination with media such as Essential 8 (Gibco) or mTeSR plus (Stemcell  
263 technologies).<sup>18,19</sup>

264

## 265 **Acknowledgements**

JF holds a PhD studentship funded through an industrial contract with IC BIOSOLUTIONS.

The Roslin Institutes receives funding from The Biotechnology and Biological Sciences  
Research Council through an Institute Strategic Programme Grant.

266

267

## 268 **References**

- 269 1. Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology:  
270 A decade of progress. *Nat Rev Drug Discov.* 2017;16(2).  
271 doi:10.1038/nrd.2016.245
- 272 2. Katayama M, Fukuda T, Kaneko T, et al. Induced pluripotent stem cells of  
273 endangered avian species. *Commun Biol.* 2022;5(1). doi:10.1038/s42003-022-  
274 03964-y
- 275 3. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse  
276 Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell.*  
277 2006;126(4). doi:10.1016/j.cell.2006.07.024
- 278 4. Steinle H, Weber M, Behring A, et al. Reprogramming of Urine-Derived Renal  
279 Epithelial Cells into iPSCs Using srRNA and Consecutive Differentiation into  
280 Beating Cardiomyocytes. *Mol Ther Nucleic Acids.* 2019;17.  
281 doi:10.1016/j.omtn.2019.07.016
- 282 5. Donadeu FX, Esteves CL. Prospects and challenges of induced pluripotent stem  
283 cells in equine health. *Front Vet Sci.* 2015;2(NOV).  
284 doi:10.3389/fvets.2015.00059
- 285 6. Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free  
286 human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai  
287 virus vectors. *Proc Natl Acad Sci U S A.* 2011;108(34).  
288 doi:10.1073/pnas.1103509108
- 289 7. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate  
290 integration-free human iPS cells. *Nat Methods.* 2011;8(5).  
291 doi:10.1038/nmeth.1591

- 292 8. Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-mediated  
293 reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem*  
294 *Cell*. 2011;8(4). doi:10.1016/j.stem.2011.03.001
- 295 9. Nagy K, Sung HK, Zhang P, et al. Induced Pluripotent Stem Cell Lines Derived  
296 from Equine Fibroblasts. *Stem Cell Rev Rep*. 2011;7(3). doi:10.1007/s12015-  
297 011-9239-5
- 298 10. Yu L, Wei Y, Sun HX, et al. Derivation of Intermediate Pluripotent Stem Cells  
299 Amenable to Primordial Germ Cell Specification. *Cell Stem Cell*. 2021;28(3).  
300 doi:10.1016/j.stem.2020.11.003
- 301 11. Chen G, Gulbranson DR, Hou Z, et al. Chemically defined conditions for  
302 human iPSC derivation and culture. *Nat Methods*. 2011;8(5).  
303 doi:10.1038/nmeth.1593
- 304 12. Wiley LA, Burnight ER, Deluca AP, et al. CGMP production of patient-specific  
305 iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness.  
306 *Sci Rep*. 2016;6. doi:10.1038/srep30742
- 307 13. Sharma R, Livesey MR, Wyllie DJA, et al. Generation of functional neurons  
308 from feeder-free, keratinocyte-derived equine induced pluripotent stem cells.  
309 *Stem Cells Dev*. 2014;23(13). doi:10.1089/scd.2013.0565
- 310 14. Quattrocchi M, Giacomazzi G, Broeckx SY, et al. Equine-Induced Pluripotent  
311 Stem Cells Retain Lineage Commitment Toward Myogenic and Chondrogenic  
312 Fates. *Stem Cell Reports*. 2016;6(1). doi:10.1016/j.stemcr.2015.12.005

- 313 15. Conner DA. Mouse embryo fibroblast (MEF) feeder cell preparation. *Current*  
314 *protocols in molecular biology* / edited by Frederick M Ausubel . [et al].  
315 2001;Chapter 23. doi:10.1002/0471142727.mb2302s51
- 316 16. Rodin S, Antonsson L, Hovatta O, Tryggvason K. Monolayer culturing and  
317 cloning of human pluripotent stem cells on laminin-521-based matrices under  
318 xeno-free and chemically defined conditions. *Nat Protoc.* 2014;9(10).  
319 doi:10.1038/nprot.2014.159
- 320 17. Braam SR, Zeinstra L, Litjens S, et al. Recombinant Vitronectin Is a  
321 Functionally Defined Substrate That Supports Human Embryonic Stem Cell  
322 Self-Renewal via  $\alpha V\beta 5$  Integrin. *Stem Cells.* 2008;26(9).  
323 doi:10.1634/stemcells.2008-0291
- 324 18. Chen G, Gulbranson DR, Hou Z, et al. Chemically defined conditions for  
325 human iPSC derivation and culture. *Nat Methods.* 2011;8(5):424-429.
- 326 19. Castro-Viñuelas R, Sanjurjo-Rodríguez C, Piñeiro-Ramil M, et al. Tips and  
327 tricks for successfully culturing and adapting human induced pluripotent stem  
328 cells. *Mol Ther Methods Clin Dev.* 2021;23. doi:10.1016/j.omtm.2021.10.013

329

## 330 **Figure Captions**

331 **Figure 1:** Representative bright field image of *bona-fide* equine iPSCs grown on  
332 MEF feeders, and showing compact colonies with defined edges. Colonies indicated  
333 by arrows displayed sustained growth over 2-5 days and were ready for picking.

334

335 **Figure 2:** Bright field images showing (A) equine iPSC colonies (indicated by  
336 arrows) which failed to adapt to feeder free conditions as shown by distinct

337 morphological changes and halted growth, and (B) iPSC population which adapted to  
338 feeder free conditions successfully, as evidenced by highly proliferative, compact  
339 colonies with well-defined edges.

340